Gregg Williams

Director Gregg Williams bought 1,587,301 shares of VANI at $1.26 for $1,999,999.26; stock now $1.13, down 41.2% from 52-week high.

Gregg Williams purchased 1,587,301 shares at $1.26 on 2026-06-15, increasing his holdings from 34,531,785 to 36,119,086 shares. The stock currently trades at $1.13, down 41.2% from its 52-week high of $1.92. His same-ticker history at VANI shows mixed results: of 5 prior buys, only 1 was well-timed at the 90-day mark, with measurable outcomes ranging from -7.1% to +17.5% over 30 days. The company reported revenue of $0.00 in the latest quarter and net income of -$6,780,000.00, with negative full-year results. The insider's cross-ticker track record shows 20 prior buys averaging +5.4% over 30 days and +5.2% over 90 days with a 58.82% win rate, but his ticker-specific performance at VANI diverges from this pattern.

Director Gregg Williams buys 1,587,301 shares of VANI at $1.26, now trading 42.7% below 52-week high; 5th VANI purchase in 3 months amid unprofitability.

Gregg Williams, a director at Vivani Medical, purchased 1,587,301 shares at $1.26 for $1,999,999.26, expanding his holdings to 34,531,785 shares (+4.8% net change). This marks the fifth documented insider purchase at VANI in a three-month window (five prior trades at this ticker ranging from 2026-02-15 to 2026-04-15), suggesting persistent accumulation. However, the underlying fundamentals present a significant concern: the company reported zero revenue in the latest quarter and a net loss of $6,780,000 over the most recent full fiscal year, with a current market cap of $94,858,614.40. Williams's prior VANI purchases have shown mixed results—his same-ticker history at VANI shows 1 of 5 prior trades were well-timed at the 90-day mark, and his more recent measurable outcomes were negative (90d returns of -7.1% and -4.0%), contrasting with his cross-ticker track record of a 58.82% win rate. The stock currently trades at $1.10, down 42.7% from its 52-week high of $1.92, raising questions about whether the director's continued buying reflects conviction in an operational turnaround or reflects the stock's depressed absolute price level.

Director Williams Gregg buys 1,587,301 shares of VANI at $1.26 for $2.0M, raising stake to 32.94M shares

Williams Gregg (Director) purchased 1,587,301 shares at $1.26 on 2026-04-15, increasing his holdings by 5.1% to 32.94M shares total and committing $1,999,999.26 in capital. The company is unprofitable with net income of $-6,530,000.00 and zero revenue in the latest quarter, while trading at $1.31 currently—30.0% below its 52-week high of $1.87. His prior same-ticker history at VANI shows mixed results: of 5 recent buys, outcomes ranged from +17.5% to -15.5% at the 30-day mark, with none yet reaching 90-day evaluation. His broader cross-ticker track record is stronger (66.67% 90-day win rate with avg 90d return +9.6%), but this ticker-specific pattern offers limited confidence that prior purchases have caught upside after the initial 30-day window.

Director Williams Gregg purchases 1,575,231 shares at blended $1.07 (2 transactions) as VANI stock trades -34.8% from 52-week high.

Director Williams Gregg executed 2 separate purchases totaling 1,575,231 shares for $1,683,334.66, increasing his holdings from 29,781,952 to 31,357,183 shares (+5.3%). The buys occurred at $1.03 and $1.26 per share on 2026-03-15, at a blended average of $1.07, while current price stands at $1.22—a position $0.19 above the weighted transaction average but -34.8% below the 52-week high of $1.87. The company reported $0.00 revenue in the latest quarter and net income of $-6,530,000.00, with annual revenue declining -100.0% year-over-year and a market cap of $89,001,726.70. At the same ticker (VANI), Gregg's prior 5 purchases showed mixed results: one measurable 90-day outcome (from 2026-01-27) registered -15.5%, with timing analysis showing 0 of 0 prior buys at this ticker well-timed at the 90-day mark, suggesting no pattern of advantageous entry timing for VANI specifically. His broader cross-ticker track record shows 20 prior buys with a 73.33% 90-day win rate, but this ticker-specific history diverges sharply from his overall record.

Director Williams Gregg purchases 1.87M shares (1,866,492) for $2.0M at blended $1.06 avg, expanding stake to 29.78M shares

Director Williams Gregg executed 2 separate purchases totaling 1,866,492 shares for $1,983,333.49 on 2026-02-15, increasing his holdings by 6.7%. The acquisitions occurred at prices ($1.03 and $1.26) near or at the current market level of $1.26, which sits 32.6% below the 52-week high of $1.87. Gregg's cross-ticker track record shows strong historical performance (20 prior buys with 86.67% 90-day win rate and +21.5% average 90-day return), but his same-ticker activity at VANI spans only recent weeks with mixed near-term results and no 90-day measurable outcomes yet. The company is unprofitable (full-year net income of $-6,530,000) with zero latest-quarter revenue and a 100% year-over-year revenue decline, creating a high-risk fundamental backdrop that contrasts with the insider's historical trading success on other securities.

Director Williams Gregg purchased 1,351,351 shares of VANI at $1.48 on 2026-01-27, adding $2.0M to a 27.92M-share position in unprofitable biotech.

Williams Gregg, a director of Vivani Medical, increased his stake by 1,351,351 shares (+5.1%) at $1.48 in late January, investing $1,999,999.48 in aggregate. This marks the fourth consecutive month of open-market purchases at the company, following buys on 2026-01-15, 2025-12-15, and 2025-11-15. His cross-ticker track record shows 92.86% win rate over 90 days with +24.9% average return, suggesting pattern recognition skill, yet this represents an accumulation into a company with $0.00 latest-quarter revenue, $-6,530,000.00 net income, and -100.0% annual revenue growth. At the current price of $1.49, the transaction sits 30.9% below the 52-week high of $1.87 and within the 52-week range, but Gregg's prior trades at VANI lack 90-day measurable outcomes, so no direct timing signal is available at this ticker. The sustained monthly purchases despite deteriorating fundamentals and the absence of positive revenue signal a director willing to accumulate deeply unprofitable equity, a pattern that warrants investor scrutiny of the underlying business case.

Director Williams Gregg purchases 1,737,765 shares ($2.0M) at blended $1.14; holdings rise to 26.56M (+7.0%)

Director Williams Gregg executed 2 separate purchases totaling 1,737,765 shares for $1,983,333.94 on 2026-01-15, increasing holdings by 7.0% to 26,564,109 shares. The blended average purchase price of $1.14 sits 16.2% below the current price of $1.36, though the stock trades 27.3% below its 52-week high of $1.87. At the same ticker, Gregg's 4 prior measurable buys show mixed 30-day outcomes (+0.8%, +13.4%, +20.5%, +7.1%), while his cross-ticker track record of 20 prior buys averaged +10.1% return over 30 days and +27.4% over 90 days with a 100% win rate. The company remains materially unprofitable (net income $-6,530,000.00 for the latest period, full-year net income was negative) with zero latest-quarter revenue and annual revenue growth of -100.0%, presenting a stark disconnect between this substantial insider acquisition and the company's operational challenges.

Director Williams Gregg buys 1,737,765 shares (1.74M) at blended avg $1.14, raising stake to 24.83M shares (+7.5%)

Williams Gregg, a director at unprofitable VANI, executed 2 separate purchases totaling 1,737,765 shares for $1,983,333.94 on 2025-12-15 at prices of $1.12 and $1.26. This increased his holdings by 7.5% to 24,826,344 shares. The transaction occurred at prices below the current market price of $1.41, but above the 52-week low of $0.96. While his cross-ticker track record shows strong 90-day performance (30 prior buys, 100% win rate, +30.1% avg), his same-ticker history at VANI shows mixed recent results: three of five prior purchases posted 30-day gains (7.1% to 26.8%), while one declined -16.0%, with 90-day outcomes not yet measurable. The company's fundamentals remain challenged: zero latest-quarter revenue and a $-6,530,000.00 net loss, with annual revenue declining -100.0%. The director's material accumulation warrants investor examination of whether this reflects conviction in a turnaround or routine portfolio management at a highly speculative microcap.

Director Williams Gregg purchased 1,737,764 shares (1.74M) at $1.14 blended average on 2025-11-15, raising stake 8.1% to 23.09M shares

Director Williams Gregg executed 2 separate purchases totaling 1,737,764 shares for $1,983,332.68, at prices of $1.12 and $1.26, with a blended average of $1.14. This increased his holdings by 8.1% to 23,088,579 shares post-transaction. At the current price of $1.47, the shares he purchased are now up 29% from the blended entry, though the stock is -21.4% from its 52-week high and down -13.0% over the past 30 days. Vivani Medical is unprofitable with $-6,530,000 net income in its most recent period and zero revenue in the latest quarter, with annual revenue growth of -100.0%, indicating a company in severe financial distress. Gregg's prior 5 trades at VANI have shown positive 30-day returns (ranging from +4.8% to +26.8%), though 90-day outcomes remain unmeasurable. His cross-ticker track record shows 20 prior buys with a 100% 90-day win rate and average 90-day return of +31.7%, but this context does not transfer to a ticker where the underlying business metrics are deteriorating severely.

Director Williams Gregg buys 3,703,703 shares of VANI at $1.62; 21.0% addition to holdings in unprofitable biotech

Director Williams Gregg purchased 3,703,703 shares (3.70M shares) of Vivani Medical at $1.62 on 2025-10-27, increasing his holdings by 21.0% to 21,350,815 shares (21.35M shares). This is a material accumulation in a company with Revenue $0.00 in the latest quarter and an annual revenue decline of -100.0%, though his cross-ticker track record shows a 90d win rate of 93.75% across 20 prior buys with an average 90d return of +29.2%. At VANI specifically, his prior four measurable trades showed positive 30-day returns (ranging +4.8% to +17.9%), with his May 2025 purchase posting +25.7% over 90 days. The stock is currently down 10.7% from its 52-week high but up 16.8% over the past 30 and 90 days, placing this purchase near recent strength rather than a contrarian moment. Investors should note that the company remains unprofitable and revenue-less, and this director's insider confidence must be weighed against the severe operational headwinds and the absence of recent positive fundamentals data.